The NM_000152.5:c.1781G>C variant in GAA is a missense variant predicted to cause substitution of arginine by proline at amino acid 594 (p.Arg594Pro). This variant has been detected in at least 3 probands with Pompe disease (PMID: 34952985, 19588081, 18425781, clinical diagnostic laboratory). Two of these individuals are reported to have clinical features consistent with the condition, and one is reported to be on enzyme replacement therapy, but residual GAA activity was not provided (PMID: 19588081, 34952985). Another patient, identified by a clinical diagnostic laboratory, has deficiency GAA activity in dried blood spot and a brother reported to have Pompe disease (PP4_Moderate). Each of the 3 probands is compound heterozygous, phase unknown, for the variant and another pathogenic variant in GAA, either c.525delT (clinical diagnostic laboratory), c.32‐13T>G (PMID: 34952985) or c.1941C>G (p.Cys647Trp) (PMID: 19588081) (PM3). The highest population minor allele frequency in gnomAD v2.1.1 is 0.00002 (2/111938 alleles) in the European (non-Finnish) population, which is lower than the ClinGen LSD VCEP’s threshold for PM2_Supporting (<0.001), meeting this criterion (PM2_Supporting). Expression of the variant in COS cells resulted in 1.2% wild type GAA activity leading the variant to be described as Class B (“potentially less severe”), indicating that this variant may impact protein function (PMID: 22644586) (PS3_Moderate). The computational predictor REVEL gives a score of 0.941 which is above the threshold of 0.7, evidence that correlates with impact to GAA function (PP3). Another missense change (c.1781G>T, p.Arg594His) at the same amino acid residue has been classified as likely pathogenic by the ClinGen LSD VCEP (PM5_Suppporting). There is a ClinVar entry for this variant (Variation ID: 289361, 1 star review status) with one submitter classifying the variant as pathogenic, 3 as likely pathogenic, and one as uncertain significance. In summary, this variant meets the criteria to be classified as likely pathogenic for Pompe disease based on the GAA-specific ACMG/AMP criteria applied, as specified by the ClinGen Lysosomal Storage Disorders Variant Curation Expert panel (Specifications Version 2.0): PM3, PS3_Moderate, PP4_Moderate, PP3, PM2_Supporting, PM5_Supporting.